Literature DB >> 2872592

Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201-995.

G Boden, I G Ryan, B L Eisenschmid, J J Shelmet, O E Owen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2872592     DOI： 10.1056/NEJM198606263142606

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  19 in total

Review 1.  Somatostatin analog therapy in treatment of gastrointestinal disorders and tumors.

Authors:  Wouter W de Herder; Steven W J Lamberts
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

2.  Preventive effects of octreotide (SMS 201-995) on diabetic ketogenesis during insulin withdrawal.

Authors:  P Diem; R P Robertson
Journal:  Br J Clin Pharmacol       Date:  1991-11       Impact factor: 4.335

Review 3.  Endocrine therapy of metastatic breast cancer.

Authors:  A Manni
Journal:  J Endocrinol Invest       Date:  1989-05       Impact factor: 4.256

4.  Bone lesions in recurrent glucagonoma: A case report and review of literature.

Authors:  Cristian Ghetie; Daniel Cornfeld; Vassilios S Ramfidis; Kostas N Syrigos; Muhammad W Saif
Journal:  World J Gastrointest Oncol       Date:  2012-06-15

5.  Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors.

Authors:  Jonathan Strosberg; Larry Kvols
Journal:  World J Gastroenterol       Date:  2010-06-28       Impact factor: 5.742

Review 6.  Somatostatin and analogues in the treatment of cancer. A review.

Authors:  B M Evers; D Parekh; C M Townsend; J C Thompson
Journal:  Ann Surg       Date:  1991-03       Impact factor: 12.969

7.  Resolution of necrolytic migratory erythema with somatostatin analogue in a patient diagnosed with pancreatic glucagonoma.

Authors:  Cristina Saavedra; Angela Lamarca; Richard A Hubner
Journal:  BMJ Case Rep       Date:  2019-08-10

8.  Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.

Authors:  R Arnold; M E Trautmann; W Creutzfeldt; R Benning; M Benning; C Neuhaus; R Jürgensen; K Stein; H Schäfer; C Bruns; H J Dennler
Journal:  Gut       Date:  1996-03       Impact factor: 23.059

9.  Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors.

Authors:  R Arnold; C Neuhaus; R Benning; W B Schwerk; M E Trautmann; K Joseph; C Bruns
Journal:  World J Surg       Date:  1993 Jul-Aug       Impact factor: 3.352

10.  Molecular challenges of neuroendocrine tumors.

Authors:  Parthik Patel; Karina Galoian
Journal:  Oncol Lett       Date:  2017-12-21       Impact factor: 2.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.